Mirum Pharmaceuticals
MIRM
205 hedge funds and large institutions have $2.19B invested in Mirum Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 74 increasing their positions, 60 reducing their positions, and 15 closing their positions.
193% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 15
23% more repeat investments, than reductions
Existing positions increased: 74 | Existing positions reduced: 60
22% more funds holding in top 10
Funds holding in top 10: 9 → 11 (+2)
15% more funds holding
Funds holding: 178 → 205 (+27)
5% more capital invested
Capital invested by funds: $2.08B → $2.19B (+$113M)
1.37% less ownership
Funds ownership: 111.73% → 110.36% (-1.4%)
84% less call options, than puts
Call options by funds: $653K | Put options by funds: $4.12M
Top Buyers
| 1 |
JP Morgan Chase
New York
|
+$14.9M |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$10.9M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$9.57M |
| 4 |
D.E. Shaw & Co
New York
|
+$6.56M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$6.34M |
Top Sellers
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
-$34.9M |
| 2 |
CCM
Cadian Capital Management
New York
|
-$18.6M |
| 3 |
State Street
Boston,
Massachusetts
|
-$17.2M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$11.6M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$9.68M |
MIRM Hedge Fund Activity: Q4 2024 in Review
205 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Mirum Pharmaceuticals (MIRM) for Q4 2024, worth a combined $2.19B — up 5.4% from $2.08B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new MIRM positions and 15 closed out — a net gain of 29 holders — while 74 added to existing stakes and 60 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $14.9M. The largest seller was Eventide Asset Management, cutting an estimated $34.9M.
- 205 institutional investors held Mirum Pharmaceuticals (MIRM) as of Q4 2024, up from 178 in Q3 2024.
- Funds reported $2.19B of Mirum Pharmaceuticals stock for Q4 2024, up 5.4% quarter-over-quarter.
- 44 funds opened new Mirum Pharmaceuticals positions in Q4 2024 and 15 closed out, a net change of +29 holders.
- The largest Mirum Pharmaceuticals buyer in Q4 2024 was JP Morgan Chase, an estimated $14.9M added.
- The largest Mirum Pharmaceuticals seller in Q4 2024 was Eventide Asset Management, an estimated $34.9M sold.
Based on aggregated 13F filings for Q4 2024.